Patents Assigned to MedImmune Limited
  • Pyrrolobenzodiazepines and targeted conjugates
    Patent number: 9713647
    Abstract: A compound, or a pharmaceutically acceptable salt or solvate thereof, or conjugates thereof, selected from the group consisting of: wherein: (a) R10 is H, and R11 is OH, ORA, where RA is saturated C1-4 alkyl; (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is SOzM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation, or both M together are a divalent pharmaceutically acceptable cation.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: July 25, 2017
    Assignees: SEATTLE GENETICS, INC., MEDIMMUNE LIMITED
    Inventors: Scott Jeffrey, Patrick Burke, Philip Wilson Howard
  • Pyrrolobenzodiazepines and targeted conjugates
    Patent number: 9707301
    Abstract: This invention relates to pyrrolobenzodiazepines (PBDs), in particular pyrrolobenzodiazepine dimers having a C2-C3 double bond and an aryl group at the C2 position in each monomer unit, and their inclusion in targeted conjugates. The differing substituent groups may offer advantages in the preparation and use of the compounds, particularly in their biological properties and the synthesis of conjugates, and the biological properties of these conjugates.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: July 18, 2017
    Assignees: SEATTLE GENETICS, INC., MEDIMMUNE LIMITED
    Inventors: Scott Jeffrey, Patrick Burke, Philip Wilson Howard
  • Methods of treating neuropathic pain with specific binding members for NGF
    Patent number: 9701746
    Abstract: Specific binding members for Nerve Growth Factor (NGF), in particular anti-NGF antibody molecules, especially human antibody molecules, and especially those that neutralize NGF activity. Methods for using anti-NGF antibody molecules in diagnosis or treatment of NGF related disorders, including pain, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, other diseases of airway inflammation, diabetic neuropathy, cardiac arrhythmias, HIV, arthritis, psoriasis and cancer.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: July 11, 2017
    Assignee: MedImmune Limited
    Inventors: Ruth Franks, Andrew Grier Buchanan, Albert George Thom, Fraser Ewing Welsh, Philip Antony Bland-Ward, Matthew Alexander Sleeman, Carl Anthony Matthews, Celia Patricia Hart, Jon Eric Hawkinson
  • ION CHANNEL MODULATORS AND USES THEREOF
    Publication number: 20170166634
    Abstract: The invention provides antibodies that specifically bind a P2X4 polypeptide and modulate P2X4 channel activity, recombinant P2X4 polypeptides and methods for generating such polypeptides, as well as compositions and methods for generating anti-P2X4 antibodies, and methods of using P2X4 antibodies for the treatment of neuropathic pain and other indications.
    Type: Application
    Filed: May 2, 2015
    Publication date: June 15, 2017
    Applicant: Medimmune Limited
    Inventors: Wendy A WILLIAMS, Clare JONES, James BUTTON, John LINLEY, Harm Jan SNIJDER, Ling HUANG, Yoko SHIBATA, Sudharsan SRIDHARAN, Maria GROVES, Claire DOBSON
  • Amino acid derivatives
    Patent number: 9670521
    Abstract: There are provided amino acid derivatives of formula V and VI as defined herein which are pyrrolysine analogs for use in bioconjugation processes.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: June 6, 2017
    Assignee: MEDIMMUNE LIMITED
    Inventors: Kenneth H. Grabstein, Michael Van Brunt, Marcello Marelli
  • TARGETED BINDING AGENTS AGAINST B7-H1
    Publication number: 20170137522
    Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
    Type: Application
    Filed: October 25, 2016
    Publication date: May 18, 2017
    Applicant: MEDIMMUNE LIMITED
    Inventors: CHRISTOPHE QUEVA, MICHELLE MORROW, SCOTT HAMMOND, MARAT ALIMZHANOV, JOHN BABCOCK, IAN Nevin FOLTZ, JASPAL SINGH KANG, LAURA SEKIROV, MELANIE BOYLE, MATTHIEU CHODORGE, ROSS A. STEWARD, KATHLEEN ANN MULGREW
  • Pyrrolobenzodiazepines and conjugates thereof
    Patent number: 9649390
    Abstract: A conjugate of formula (A):
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 16, 2017
    Assignee: MEDIMMUNE LIMITED
    Inventors: Philip Wilson Howard, John A. Flygare, Thomas Pillow, Binqing Wei
  • Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases
    Patent number: 9624227
    Abstract: A compound with the formula I:
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: April 18, 2017
    Assignee: MEDIMMUNE LIMITED
    Inventors: Philip Wilson Howard, Stephen John Gregson, Luke Masterson
  • Targeted pyrrolobenzodiazapine conjugates
    Patent number: 9592240
    Abstract: Provided are Conjugate comprising PBDs conjugated to a targeting agent and methods of using such PBDs.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: March 14, 2017
    Assignees: SEATTLE GENETICS INC., MEDIMMUNE LIMITED
    Inventors: Philip Wilson Howard, Scott Jeffrey, Patrick Burke, Peter Senter
  • Methods for binding members of interleukin-4 receptor ? (IL-4R?)
    Patent number: 9587027
    Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: March 7, 2017
    Assignee: MEDIMMUNE LIMITED
    Inventors: Per-Olof Fredrik Eriksson, Karin Von Wachenfeldt, Emma Suzanne Cohen, Claire Louise Dobson, Deborah Louise Lane
  • Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
    Patent number: 9567340
    Abstract: A compound of formula I: or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: February 14, 2017
    Assignee: MEDIMMUNE LIMITED
    Inventor: Philip Wilson Howard
  • Pyrrolobenzodiazepines and conjugates thereof
    Patent number: 9562049
    Abstract: A compound with the formula I: and salts and solvates thereof.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: February 7, 2017
    Assignee: MEDIMMUNE LIMITED
    Inventor: Philip Wilson Howard
  • Pyrrolobenzodiazepines and targeted conjugates
    Patent number: 9526798
    Abstract: A compound, or a pharmaceutically acceptable salt or solvate thereof, or conjugates thereof, selected from the group consisting of formula wherein: (a) R10 is H, and R11 is OH, ORA, where RA is saturated C1-4 alkyl; (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is S02M, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation, or both M together are a divalent pharmaceutically acceptable cation.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: December 27, 2016
    Assignees: SEATTLE GENETICS, INC., MEDIMMUNE LIMITED
    Inventors: Scott Jeffrey, Patrick Burke, Philip Wilson Howard
  • THERAPEUTIC COMBINATIONS AND METHODS FOR TREATING NEOPLASIA
    Publication number: 20160347848
    Abstract: Provided herein are methods of treating a solid tumor comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof, tremelimumab or an antigen-binding fragment thereof, and MEDI6383.
    Type: Application
    Filed: May 9, 2016
    Publication date: December 1, 2016
    Applicant: MedImmune Limited
    Inventors: Scott A. HAMMOND, Kathleen Ann MULGREW, Michael OBERST, Edward BRADLEY, Ross A. STEWART
  • Targeted binding agents against B7-H1
    Patent number: 9493565
    Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: November 15, 2016
    Assignee: MedImmune Limited
    Inventors: Christophe Queva, Michelle Morrow, Scott Hammond, Marat Alimzhanov, John Babcock, Ian Nevin Foltz, Jaspal Singh Kang, Laura Sekirov, Melanie Boyle, Matthieu Chodorge, Ross A. Steward, Kathleen Ann Mulgrew
  • PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF
    Publication number: 20160310611
    Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.
    Type: Application
    Filed: December 16, 2014
    Publication date: October 27, 2016
    Applicants: Genentech Inc., Medimmune Limited
    Inventors: John FLYGARE, Janet GUNZNER-TOSTE, Thomas PILLOW, Brian SAFINA, Vishal VERMA, Binqing WEI, Guiling ZHAO, Leanna STABEN, Philip Wilson HOWARD, Luke MASTERSON
  • Specific Binding Members for NGF
    Publication number: 20160297878
    Abstract: Specific binding members for Nerve Growth Factor (NGF), in particular anti-NGF antibody molecules, especially human antibody molecules, and especially those that neutralise NGF activity. Methods for using anti-NGF antibody molecules in diagnosis or treatment of NGF related disorders, including pain, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, other diseases of airway inflammation, diabetic neuropathy, cardiac arrhythmias, HIV, arthritis, psoriasis and cancer.
    Type: Application
    Filed: April 18, 2016
    Publication date: October 13, 2016
    Applicant: MedImmune Limited
    Inventors: Ruth Franks, Andrew Grier Buchanan, Albert George Thom, Fraser Ewing Welsh, Philip Antony Bland-Ward, Matthew Alexander Sleeman, Carl Anthony Matthews, Celia Patricia Hart, Jon Eric Hawkinson
  • Anti-Siglec-15 antibodies and uses thereof
    Patent number: 9447192
    Abstract: This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: September 20, 2016
    Assignees: MEDIMMUNE LIMITED, CAMBRIDGE ENTERPRISE LIMITED
    Inventors: John Elvin, Catherine Huntington, John Trowsdale, Alexander Barrow, Huan Cao
  • Factor II and fibrinogen for treatment of haemostatic disorders
    Patent number: 9433664
    Abstract: The present invention relates to normalizing impaired haemostasis comprising administering a clotting factor treatment selected from the group consisting of (1) FII; (2) PCC; and (3) a three factor combination of FH, FX and FVIIa. The clotting factor treatment can be administered in combination with fibrinogen. The clotting factor(s) can be recombinant human clotting factor(s).
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: September 6, 2016
    Assignee: MEDIMMUNE LIMITED
    Inventors: Ann Lovgren, Kenny Hansson
  • RSV-SPECIFIC BINDING MOLECULE
    Publication number: 20160251412
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Application
    Filed: February 12, 2016
    Publication date: September 1, 2016
    Applicant: MedImmune Limited
    Inventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda